- Ohr Pharmaceutical (OHRP) is raising $18M by selling 1.8M shares at $10 a piece to institutional and accredited investors in a registered direct offering.
- Ohr will use the money for general corporate purposes, including for its OHR-002 wet-AMD study and for trials of its Squalamine eye drops for the treatment of diabetic macular edema.
- Ohr expects interim data on the OHR-002 study this quarter and final data in Q1 2015.
- Shares are -17%. (PR)
From other sites
at Zacks.com (Mar 3, 2015)
at Benzinga.com (Feb 26, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs